Pharma CEO Martin Shkreli Regrets Not Pricing $750 Pill Higher
- 8 years ago
During a recent interview at a healthcare event, Martin Shkreli admitted that he regrets not pricing the drug Daraprim even higher than he did initially despite the 5,000 percent increase and subsequent backlash.
The head of Turing Pharmaceuticals, Martin Shkreli, continues to generate controversy.
At a recent healthcare event, he was asked about any regrets he had about raising the price of the drug Daraprim from $13.50 per pill to $750--a move that has been highly criticized.
According to Forbes, which hosted the event, he responded, “I would have raised prices higher.”
And he
The head of Turing Pharmaceuticals, Martin Shkreli, continues to generate controversy.
At a recent healthcare event, he was asked about any regrets he had about raising the price of the drug Daraprim from $13.50 per pill to $750--a move that has been highly criticized.
According to Forbes, which hosted the event, he responded, “I would have raised prices higher.”
And he